Aktienanalyse zu Indivior Pharmaceuticals Inc (INDV)INDVIndivior Pharmaceuticals Inc

Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Indivior PLC is currently not a strong buy due to its low RSI of 15.316, indicating it is oversold, and a significant recent price drop of 9.43% over the last five days. However, the company has a forward P/E of 9.4607, suggesting potential undervaluation, and analysts have set a price target of $53, which implies a potential upside of 63.3% from the current price of $32.45. The main risk is the recent performance trend, with a year-to-date change of -9.18%.